Evonik’s Tippecanoe Laboratories Marks 4 Million Hours Without Lost Time Accident
Milestone Demonstrates Workforce’s Continuing Commitment to Safety
Employees at Evonik Degussa Corporation’s Tippecanoe Laboratories have worked over 4 million hours without a Lost Time Accident (LTA) – a work-related injury or illness resulting in a day away from work.
“This is an incredible accomplishment for our employees and management. It demonstrates everyone’s team work and attention to detail in day-to-day activities, which prevents accidents resulting in injuries,” said Gerwin Specka, Tippecanoe Laboratories site manager. “We constantly stress the importance of always being alert to workplace hazards and empowering employees to respond promptly to any safety concerns.”
Specka noted that Tippecanoe Laboratories schedules frequent audits, inspections, and regular safety meetings as well as continuous training.
A ceremony was held on January 26, 2012, to recognize the milestone and honor the employees’ hard work and dedication to safety.
“Our employees are the backbone and driving force of the company. Their safety is always our first priority and an essential aspect of our every day operations,” said Kenny McCleary, director of Environmental Health Safety & Security at Tippecanoe Laboratories. “It’s always great to achieve such milestones but we are more concerned about our employees returning home to their families safely each day than setting records.”
Tippecanoe Laboratories manufactures a variety of specialty chemicals for ingredients in pharmaceutical medications that treat cancer, osteoporosis, lymphoma and fibromyalgia.
For additional information about Evonik in North America, please visit our website: www.evonik.com/north-america.
Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. In 2010 about 80 percent of the Group’s chemicals sales came from activities where it ranks among the market leaders. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2010 more than 34,000 employees generated sales of around €13.3 billion and an operating profit (EBITDA) of about €2.4 billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.